Diabetes
| T2D & GLP-1 RA
Diabetes
T2D & GLP-1 RA
Discovery of HDM1002, a selective, potent, oral small-molecule GLP-1R agonist for treatment of type 2 diabetes and obesity
book_2
Source:
EASD 2023 - Short Oral Session
calendar_today
Published on Medfyle:
October 2023
In this medfyle
Preclinical data indicate that oral HDM1002 has a favorable safety and tolerability profile that is consistent with peptide GLP-1 RAs.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.
